Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

Matteo S. Carlino, Adil Daud, Dirk Schadendorf et al.|European Journal of Cancer|2018

Cited by 98